Rocket Lab heads into the week of June 9 down 12% on the week and 4.8% on Tuesday alone — but this time the move looks less like a stock-specific story and more like a sector-wide flush.
The peer group makes that clear. Close correlate LUNR fell 30.6% on the week. VOYG dropped 21%. FLY lost 22.9% and RDW shed 23.5%. Rocket Lab's 12% decline looks almost orderly by comparison. The selling is broad-based across commercial space and defense-adjacent names, not a signal about Rocket Lab specifically.
What's notable in the positioning data is how little it corroborates a bearish crowding thesis. Short interest holds at 5.7% of free float — meaningful, but down 3% on the week and 10% over the past month as shorts have been steadily covering since early May. The lending market is extremely loose: availability runs at roughly 1,788%, meaning there are far more shares available to borrow than are currently borrowed. Cost to borrow sits at just 0.44%, well within the low range it has occupied all year. None of that is the fingerprint of a market leaning hard against this stock. The options market tells a similar story — the put/call ratio at 0.74 is actually running below its 20-day average of 0.79, nearly 1.6 standard deviations on the call-heavy side. Investors are buying relatively more calls than usual, not hedging aggressively into the decline.
The insider selling thread from the previous note continues. Director Alexander Slusky sold a further 40,000 shares on June 2 at $123.60 — around $4.9 million — following the cluster of C-suite sales on May 28 that were flagged last week. The 90-day net figure of roughly $42 million positive remains inflated by Peter Beck's 5-million-share addition to the register; strip that out and the pattern is a consistent stream of senior management exits into what was, until recently, a $140–150 stock. These remain orderly disposals with low significance scores, not distress signals — but the cadence has not let up even as the stock has given back considerable ground from its highs.
On valuation, the multiples are difficult to anchor in traditional terms — a price-to-book of 36x and an EV/EBITDA north of 2,000x reflect the pre-profitability growth stage. The EPS surprise factor score of 92 is the standout, placing Rocket Lab near the top of its universe for consistently beating estimates. The short score has drifted down from 40 to 38 over the past two weeks, consistent with the modest short covering trend. The ORTEX short score rank sits in the 36th percentile — not a high-conviction short setup by any measure.
The next scheduled catalyst is Q2 earnings on August 6. Between now and then, the stock's behaviour will be shaped by whether the sector-wide selling pressure stabilises, whether insider sales continue at current pace as the stock trades in the $100–110 range rather than $145–150, and whether the defense demand narrative — underpinned by the DoD bulk-buy agreement noted in recent context — can reassert itself as a floor.
See the live data behind this article on ORTEX.
Open RKLB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
